Transdiscal administration of cycline compounds

Details Transdiscal administration of cycline compounds Transdiscal administration of cycline compounds

2003-08-13

2009-06-30

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

3,10-dihydroxy-2-naphthacene carboxamide or derivative doai

C514S154000

Reexamination Certificate

active

07553827

ABSTRACT:
The present invention relates to injecting a cycline compound into a diseased intervertebral disc.

REFERENCES:
patent: 3678158 (1972-07-01), Sussman
patent: 4341867 (1982-07-01), Johansen
patent: 4427649 (1984-01-01), Dingle et al.
patent: 4435506 (1984-03-01), Jackson et al.
patent: 4696816 (1987-09-01), Brown
patent: 5095037 (1992-03-01), Iwamitsu et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5223248 (1993-06-01), McNamara et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5258371 (1993-11-01), Golub et al.
patent: 5270300 (1993-12-01), Hunziker
patent: 5368841 (1994-11-01), Trauner et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5510370 (1996-04-01), Hock
patent: 5602156 (1997-02-01), Kohn et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5656644 (1997-08-01), Adams et al.
patent: 5728396 (1998-03-01), Peery et al.
patent: 5833984 (1998-11-01), Eibl et al.
patent: 5942499 (1999-08-01), Radomsky
patent: 5965583 (1999-10-01), Beers et al.
patent: 6049026 (2000-04-01), Muschler
patent: 6277969 (2001-08-01), Le et al.
patent: 6284471 (2001-09-01), Le et al.
patent: 6294170 (2001-09-01), Boone et al.
patent: 6340369 (2002-01-01), Ferree
patent: 6352557 (2002-03-01), Ferree
patent: 6419944 (2002-07-01), Tobinick
patent: 6541477 (2003-04-01), Goehring et al.
patent: 6554830 (2003-04-01), Chappius
patent: 6590081 (2003-07-01), Zhang
patent: 6593310 (2003-07-01), Cullis-Hill
patent: 6623472 (2003-09-01), Reinecke et al.
patent: 6713246 (2004-03-01), Reinecke et al.
patent: 6756215 (2004-06-01), Wolfraim et al.
patent: 2001/0006948 (2001-07-01), Kang et al.
patent: 2001/0016195 (2001-08-01), Tobinick
patent: 2001/0026801 (2001-10-01), Tobinick
patent: 2002/0010471 (2002-01-01), Wironen et al.
patent: 2002/0026244 (2002-02-01), Trieu
patent: 2002/0032155 (2002-03-01), Ferree
patent: 2002/0082697 (2002-06-01), Damien
patent: 2002/0107200 (2002-08-01), Chang et al.
patent: 2002/0169162 (2002-11-01), Smith et al.
patent: 2002/0198599 (2002-12-01), Haldimann
patent: 2003/0007972 (2003-01-01), Tobinick
patent: 2003/0039651 (2003-02-01), Olmarker
patent: 2003/0049256 (2003-03-01), Tobinick
patent: 2003/0069639 (2003-04-01), Sander et al.
patent: 2003/0134792 (2003-07-01), Pike et al.
patent: 2003/0207827 (2003-11-01), Boyle et al.
patent: 2003/0220692 (2003-11-01), Shapiro et al.
patent: 2004/0022864 (2004-02-01), Freyman et al.
patent: 2004/0126372 (2004-07-01), Banerjee et al.
patent: 2004/0193274 (2004-09-01), Trieu
patent: 2004/0228853 (2004-11-01), Serhan et al.
patent: 2004/0229786 (2004-11-01), Attawia et al.
patent: 2004/0229878 (2004-11-01), DiMauro et al.
patent: 2005/0025765 (2005-02-01), DiMauro et al.
patent: 2005/0038001 (2005-02-01), Attawia et al.
patent: 2005/0100538 (2005-05-01), Mohamed et al.
patent: 2005/0112091 (2005-05-01), DiMauro et al.
patent: 2005/0282783 (2005-12-01), Bujoli et al.
patent: 2007/0237777 (2007-10-01), DiMauro et al.
patent: 2007/0269413 (2007-11-01), Serhan et al.
patent: 2008/0213261 (2008-09-01), DiMauro et al.
patent: 2003/266340 (2004-03-01), None
patent: 0 218 868 (1987-04-01), None
patent: 0 288 088 (1988-10-01), None
patent: 0 438 234 (1991-07-01), None
patent: 0 950 417 (1999-02-01), None
patent: 1 133 995 (2001-09-01), None
patent: 1 153 607 (2001-11-01), None
patent: 1 464 307 (2004-10-01), None
patent: WO 91/02078 (1991-02-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 92/16553 (1992-10-01), None
patent: WO 93/16099 (1993-08-01), None
patent: WO 97/28828 (1997-08-01), None
patent: WO 98/24477 (1998-06-01), None
patent: WO 99/45923 (1999-09-01), None
patent: WO 01/85179 (2001-11-01), None
patent: WO 02/057240 (2002-07-01), None
patent: WO 02/100387 (2002-12-01), None
patent: WO 03/000190 (2003-01-01), None
patent: WO 2004/022078 (2004-03-01), None
patent: WO 2005/000283 (2005-01-01), None
patent: WO 2005/011689 (2005-02-01), None
patent: WO 2005/049055 (2005-06-01), None
patent: WO 2005/053795 (2005-06-01), None
patent: WO 2005/110276 (2005-11-01), None
patent: WO 2006/031376 (2006-03-01), None
Haro, H. et al., “Matrix Metalloproteinase-7-Dependent Release of Tumor Necrosis Factor-α in a Model of Herniated Disc Resorption,”J. Clin. Invest., 105(2):143-150 (2000).
Ahn, N. U., et al., “Effect of Nutrient Concentration and OP-1 on the Metabolism of Intervertebral Disc: In Vitro Organ Culture Study,” 28, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
Allai, F., et al., “Increase in Bone Mineral Density of Patients with Spondyloarthropathy Treated With Anti-Tumor Necrosis Factor α,”Ann. Rheum. Dis., 62:347-349 (2003).
Andonopoulos, A.P., et al., “Intra-articular Anti-Tumor Necrosis Factor α Antibody in Recalcitrant Arthritis of Behçet's Disease,”Clinical and Experimental Rheumatology 21(4 Suppl 30): S-57-S58 (Jul.-Aug. 2003).
Arai, I., et al., “Pretreatment with Loxoprofen Sodium, 6-OHDA or Anti TNF-Alpha Antibody Reduce Fos-Like Immunoreactivity in Rat Experimental Lumber Disc Herniation,” 111,Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
Ariga, K., et al., “Mechanical Stress-Induced Apoptosis of Endplate Chondrocytes in Organ-Cultured Mouse Intervertebral Discs,”Spine, 28(14): 1528-1533 (2003).
Ashkenazi, A., et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin,” Proc. Natl. Acad. Sci. USA, 88, pp. 10535-10539.
Baker, D., et al., “Control Established Experimental Allergic Encephalomyelitis by Inhibition of Tumor Necrosis Factor (TNF) Activity Within the Central Nervous System using Monoclonal Antibodies and TNF Receptor-Immunoglobulin Fusion Proteins,”Eur. J. Immunol., 24:2040-2048 (1994).
Biskobing, D. M., “Novel Therapies for Osteoporosis,”Expert Opinion Invest. Drugs, 12(4): 611-621 (2003).
Braun, J. and Sieper J., “Overview of The Use of The Anti-TNF Agent Infliximab in Chronic Inflammatory Diseases,”Expert Opin. Biol. Ther. 3(1):141-168 (2003).
Braun, J., et al., “Anti-Tumour Necrosis Factor Therapy for Ankylosing Spondylitis: International Experience,”Ann. Rheum. Dis., 61(Supp. III):iii51-iii60 (2002).
Bokarewa, M., et al., “Local Infusion of Infliximab for the Treatment of Acute Joint Inflammation,”Ann. Rheum. Dis., downloaded from ard.bmjjournals.com on Nov. 30, 2005, www.annrheumdis.com 62:783-784 (2003).
Bringman, T.S. et al., “Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural Probes,”Hybridoma, 6(5):489-507 (1987).
Burke, J. G., et al., “Human Nucleus Pulposus Secretes Transforming Growth Factor Beta-1 and Basic Fibroblast Growth Factor,” 189,Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
Butler, D. et al., “TNF Receptor Fusion Proteins are Effective Inhibitors of TNF-Mediated Cytotoxicity on Human KYM-1D4 Rhabdomyosarcoma Cells,”Cytokine, 6(6):616-623 (1994).
Capon, D. et al. “Designing CD4 Immunoadhesins for AIDS Therapy,” Nature, 337:525-531 (1989).
Cardone, D., et al., “Diagnostic and Therapeutic Injection of the Hip and Knee,”Am. Fam. Physician, 67(10): 2147-2152 (2003).
Connolly, J., et al., “Development of an Osteogenic Bone-Marrow Preparation,”J. of Bone and Joint Surgery, Inc., 71-A (5): 684-691 (1989).
Conti, F., et al., “Successful Treatment With Intraarticular Infliximab for Resistant Knee Monarthritis in a Patient With Spondylarthropathy,”Arthritis&Rheumatism, 52(4): 1224-1226 (2005).
Corcoran, A.E. et al., “Characterization of Ligand Binding by the Human p55 Tumour-Necrosis-Factor Receptor,”Eur. J. B

Affiliated with

Also associated with

Rating

Transdiscal administration of cycline compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transdiscal administration of cycline compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdiscal administration of cycline compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4139383